CSCIF — COSCIENS Biopharma Inc.
—
OTC ·
Materials ·
Chemicals ·
CIK 1113423 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,888,000 | 793,000 | -730,000 | 10,757,000 | 18,841,000 | 5,005,000 | 3,522,000 |
| Dec 2025 | 1,766,000 | 609,000 | -2,388,000 | -2,183,000 | 21,431,000 | 7,307,000 | 17,589,000 |
| Sep 2025 | 1,483,000 | 621,000 | -2,007,000 | -1,819,000 | 23,859,000 | 8,524,000 | 18,779,000 |
| Jun 2025 | 2,749,000 | 974,000 | -2,353,000 | -2,701,000 | 27,558,000 | 9,333,000 | 20,461,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,473,000
Investing CF
$-458,000
Financing CF
$-407,000
CapEx
$-1,019,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.43
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-20,508,000
Inventory
$1,307,000
Receivables
$1,261,000
ST Investments
—
EBIT TTM
$-10,179,000
Pretax Income TTM
$-10,347,000
Interest Exp TTM
$168,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,999,000
EBITDA
$-7,570,000
Free Cash Flow
$-7,415,625
Enterprise Value
$2,972,377
Total Cash
$5,005,000
Total Debt
$2,023,000
Shares Out
3,184,159
Trailing EPS
$-2.48
Book Value
$4.81
ROE
-61.8%
ROA
-21.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,498,000 | -10,365,000 | -10,358,000 | 21,431,000 | 17,589,000 | — | -8,473,000 |
| Dec 2024 | 9,587,000 | -14,023,000 | -15,309,000 | 35,070,000 | 21,909,000 | — | -14,568,000 |
| Dec 2023 | 7,143,000 | -4,629,000 | -3,485,000 | 23,745,000 | 2,710,000 | — | -2,582,000 |
| Dec 2022 | 14,572,000 | 4,320,000 | 3,448,000 | 27,803,176 | 4,012,218 | — | 5,229,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PG | PROCTER & GAMBLE Co | $332.90B | $142.96 | — |
| LIN | LINDE PLC | $238.09B | $514.97 | — |
| UL | UNILEVER PLC | $123.97B | $57.07 | — |
| CL | COLGATE PALMOLIVE CO | $71.90B | $89.85 | — |
| ECL | ECOLAB INC. | $71.55B | $254.23 | — |
News headlines (Yahoo Finance, 1h cache)
COSCIENS Biopharma Inc. Reports Q1 2026 Results
2026-05-12 21:05 · Yahoo
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
2026-04-20 12:00 · Yahoo
COSCIENS Comments on Unusual Market Activity
2026-04-07 21:10 · Yahoo
COSCIENS Biopharma: Q4 Earnings Snapshot
2026-03-25 21:34 · Yahoo
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-25 21:05 · Yahoo
Upcoming Meeting Dates - March 23, 2026
2026-03-23 04:00 · Yahoo
COSCIENS Biopharma to Stop Funding Aeterna Zentaris GmbH and Zentaris IVF GmbH
2026-03-06 12:12 · Yahoo
COSCIENS Provides Strategic Update
2026-03-05 22:10 · Yahoo
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
2025-12-01 22:05 · Yahoo
COSCIENS Biopharma Inc. Announces Leadership Change
2025-11-14 22:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.